Armata Pharmaceuticals announces press release availability
ARMP•FDA agrees on initial pediatric study plan for AP-SA02
- Armata Pharmaceuticals disclosed FDA agreement on an initial pediatric study plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
- The plan supports a future BLA path, setting a pediatric development framework alongside the adult program.
- Pediatric study deferred until adult Phase 3 safety and efficacy data; adult Phase 3 expected to start in 2H 2026.
